ASLAN Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic Dermatitis

NEXT STORY
Global Cell Therapy Market, 2018-2019: Companies to Action (C2A) Profiles, Segmented by Tier
PREV STORY
Oncology Venture ingår samarbeten med ledande tyska och danska läkarnätverk och etablerar laboratorium i Berlin för att utveckla precisionsmedicin mot cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

ASLAN Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic Dermatitis

NEXT STORY
Global Cell Therapy Market, 2018-2019: Companies to Action (C2A) Profiles, Segmented by Tier
PREV STORY
Oncology Venture ingår samarbeten med ledande tyska och danska läkarnätverk och etablerar laboratorium i Berlin för att utveckla precisionsmedicin mot cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis

MECHELEN, Belgium, Sept. 6, 2016 (GLOBE NEWSWIRE) -- Galapagos (Euronext & NASDAQ: GLPG) announces ...

author_avatar
NASDAQ Market News

Aptose Reports Results for the Third Quarter Ended September 30, 2018

Conference call is scheduled for tomorrow, Wednesday, November 7th at 8:00 AM ET SAN ...

author_avatar
NASDAQ Market News

SinfoníaRx Now Provides Access to Pharmacists’ Advice on Medication and Diabetes Through Their Partnership with Ventanilla de Salud Participants in Tucson

TUCSON, Ariz., June 16, 2016 (GLOBE NEWSWIRE) -- “Ventanilla de Salud” (VDS) which translates ...

author_avatar
NASDAQ Market News